呼吁改善临床和认知评估,以缩小粉样蛋白/粉样蛋白病理发作和认知功能障碍检测之间的差距
Jordi A Matias-Guiu1, Rosie E Curiel-Cid2,3, Bruce P Hermann4
1Department of Neurology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain.
Journal of the American Geriatrics Society
|April 1, 2025
概括
新的阿尔茨海默病 (AD) 标准需要更好的临床和认知工具来将生物标志物发现与个体患者的症状联系起来. 提出的解决方案旨在弥合生物学和临床差距,改善早期发现认知衰退.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
背景情况:
- 目前阿尔茨海默病 (AD) 的定义和诊断标准正在不断发展,特别是随着生物学和临床生物学方法的进步.
- 需要更好地将生物标志物数据与临床表现相结合,以便准确诊断和患者管理.
研究的目的:
- 讨论关于阿尔茨海默病定义和标准的新观点.
- 提出改善AD生物标志物与AD临床表现之间的联系的策略.
- 提高个人层面对病理生理过程的理解.
主要方法:
- 对AD诊断的现有和新兴方法进行审查和评论.
- 提出新的临床和认知工具,包括"认知压力测试"和数字临床生物标志物.
- 强调需要精细的纵向规范性数据收集和增强的临床技能.
主要成果:
- 该评论主张继续专注于改进临床和认知评估工具.
- 拟议的策略旨在将生物标志物发现置于个体患者轨迹中的背景.
- 生物和临床生物方法的整合对于有效的AD管理至关重要.
结论:
- 开发先进的临床工具和增强的分析程序可以帮助缩短AD的临床前阶段.
- 弥合生物标志物异常和认知功能障碍发作之间的差距至关重要.
- 改进的诊断策略将导致对阿尔茨海默病的更有效的早期发现和干预.
相关概念视频
Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
Dementia
76
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
76
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86
Cognitive Development During Adulthood
34
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
34


